Skip to main content

Table 2 Statistical data of study’s patients

From: Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study

 

Lipiodol

Lipiodol+EmboCept®S

p-value

Number of patients

51

48

0.584

➢ female

13

8

 

➢ male

38

40

 

Age of patients (years)

63.8

63.4

0.972

Number of TACE

283

384

0.421

Presence of liver cirrhosis (%)

38

53

 

Initial liver disease:

 Hepatitis B

10

19

 

 Hepatitis C

23

13

 

 Hepatitis B and C

6

3

0.643

 Hemochromatosis

1

2

 

 Alcohol abusus

13

13

 

BCLC-Stage:

 BCLC-Stage A

3

5

0.194

 BCLC-Stage B

35

56

 

Child-Pugh class:

 A

9

18

0.206

 B

36

36

 

Localisation in liver:

 Right lobar

22

23

 

 Left lobe

3

2

0.310

 Bilobar

19

30

 

Number of tumor lesions:

 Single

8

3

 

 2

28

0

 

 3

8

0

0.252

 4

4

0

 

 Multifocal

0

48

 

Tumor response:

 Partial response

11

14

0.211

 Stable disease

32

22

 

 Progressive disease

8

12